With the expansion of the reimbursement criteria for onasemnogene abeparvovec, the first gene therapy approved in Italy for the treatment of spinal muscular atrophy (Sma), even children with spinal muscular atrophy type 2 (Sma2) have the possibility of accessing the 'innovative treatment. The green light from Aifa for the reimbursement of gene therapy for this category of patients was announced by Novartis in the press conference organized in Rome.
#Rare #diseases #gene #therapy #children #Sma2
